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We investigated whether development of mutations leads to loss of CD8 T-cell recognition in HIV-1 infection and is possibly linked to
alterations in HIV-1-specific CD4+ T-cell responses in 2 HIV-infected individuals. In patient, H434 full genome sequencing of HIV-1 biological
clones at early and late time points during disease progression showed development of fixed mutations in 16 predicted HIV-specific CTL epitopes.
Loss of T-cell recognition and reactivity against wild-type and mutant epitopes was observed primarily for the HLA-B27-restricted KK10 epitope
and HLA-A2-restricted SL9 epitope. Similarly, in patient H671, decreasing numbers of HLA-A3-restricted CD8+ T cells specific for the wild-type
RK9 epitope was observed after CTL escape. Only in patient H434 loss of CTL responses was paralleled by a decrease in HIV-specific IL-2+
CD4+ T-helper responses. This suggests that loss of T-cell reactivity may not be directly linked to HIV-specific CD4+ T-cell responses but that
increased viremia after CTL escape may influence CD4+ T-helper responses.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV; Escape; CTL; CD4; CD8; MutationIntroduction
Cellular immune responses play a pivotal role in the control
of HIV-1 infection. Resolution of acute viremia was shown in a
number of studies to correlate with the development of strong
CD8+ T-cell responses in the natural history of HIV-1 infection
(Koup et al., 1994; Borrow et al., 1994; Wilson et al., 2000b).
During chronic HIV-1 infection, HIV-specific CD8+ T-cell
numbers correlated inversely with viral load (Greenough et al.,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.09.023
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1 Contributed equally to this paper.1997; Ogg et al., 1998), and high numbers of HIV-specific
CD8+ T cells have been associated with delayed HIV disease
progression (Ogg et al., 1999). Furthermore, depletion of CD8+
T cells in simian immunodeficiency virus (SIV)-infected
macaques has been reported to result in increased viremia
(Jin et al., 1999; Schmitz et al., 1999) which was subsequently
reversed by the restoration of CD8+ T cells. Escape from CD8+
T-cell recognition through mutation of cytotoxic T-lymphocyte
(CTL) epitopes, and the subsequent failure of HIV-specific
CD8+ T cells to eliminate HIV-1-infected cells, has proven to
be a major means whereby HIV-1 evades HIV-1-specific
cellular immune responses, leading to disease progression
and ultimately AIDS (Letvin and Walker, 2003). Evidence that
escape may lead to loss of immune control by CTL as was
originally described by Goulder et al. (1997) and has since
been confirmed by others (Price et al., 1997; Borrow et al.,6) 209 – 219
www.e
Fig. 1. Clinical parameters for patients H434 and H671. Longitudinal analyses
of serum HIV RNA load (solid line) and CD4+ T-cell numbers (dotted line) are
shown for patient H434 (A) and H671 (B). Follow up is given in months post
seroconversion on the x axis. Asterisks indicate the time points from which
biological clones from patient H434 (A) were subjected to whole genome
analysis (Table 1). Arrows on the x axis indicate time points at which T-cel
responses were measured (Figs. 3 and 4).
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HIV-1 infection precedes progression to AIDS. In addition,
CTL escape mutations have been reported in the SIV macaque
model, both in the acute (Allen et al., 2000; O’Connor et al.,
2002) and in the chronic phase of natural SIV infection
(Friedrich et al., 2004) and have also been described in
vaccinated rhesus macaques (Barouch et al., 2003). Mutations
of residues within epitopes can affect loading of the peptide
into the MHC class I molecule or inhibit proper T-cell
activation. Alternatively, mutations outside CTL epitopes can
influence antigen processing and thereby alter HIV-specific
CD8+ T-cell function (Draenert et al., 2004; Allen et al., 2004).
It has been shown previously that, although numbers of HIV-1-
specific tetramer+ CD8+ T cells persist at high frequencies
during progression to AIDS, numbers of IFNg-producing
CD8+ T cells decrease (Kostense et al., 2001, 2002). Thus,
loss of HIV-specific CD8+ T-cell function rather than physical
depletion of these cells may explain the failing control of
viremia during progression to AIDS. Loss of HIV-specific
CD8+ T-cell function may be a consequence of impaired
maturation as loss of proliferative capacity and expression of
perforin of HIV-specific CD8+ T cells have been associated
with progressive disease (Migueles et al., 2002). Furthermore,
the majority of HIV-specific CD8+ T cells express typical
memory markers like CD27 and are therefore not fully
differentiated (Appay et al., 2000; Champagne et al., 2001;
van Baarle et al., 2002; Jansen et al., 2004). Alternatively, loss
of function may be due to CTL escape, causing mutations
within CD8+ T-cell epitopes that influence TCR binding or
functionality of the corresponding CD8+ T cell.
Another explanation for impaired functionality of HIV-
specific CD8+ T cells may be the loss of CD4+ T-cell help.
Several studies now reported T-helper dependence of specific
CD8+ T-cell functions (Matloubian et al., 1994; Zajac et al.,
1998; Kalams et al., 1999). Interestingly, more HIV-specific
IL-2-producing CD4+ T cells and CD4+ T-helper cells
producing both IL-2 and IFNg were reported in long-term
non-progressors (LTNP) compared to progressors (Wilson et
al., 2000a). Furthermore, the presence of these cells was found
to be inversely related to viremia (Boaz et al., 2002; Harari et
al., 2004), compatible with proliferative CD4+ T-cell responses
(Rosenberg et al., 1997; Pontesilli et al., 1999; Palmer et al.,
2004). In this study, full genome sequencing of HIV-1 was
performed to determine whether genotypic alterations affected
T-cell recognition in a qualitative and quantitative manner.
Furthermore, Gag-specific CD4+ T-cell responses were mea-
sured at several time points in the course of HIV infection in
order to investigate whether the increase in viremia after CTL
escape may be linked to alterations in HIV-specific CD4+ T-
helper responses.
Results
Identification of CTL escape in HIV-1-infected patients
We selected two patients (H434, H671) who demonstrated
a sudden increase in HIV-1 viral load after several years ofviral control without the occurrence of X4 variants (Fig. 1). In
patient H671, a switch in viral phenotype to an SI variant
occurred after the increase in viral load at 62 months post-
seroconversion (mo. psc.), however, no subsequent increase in
viral load was associated with the switch. From these two
patients, we choose to select time points corresponding to
low, increasing and high viral loads to monitor the association
of CTL escape mutations with alterations in HIV-1-specific T
cellular responses. We previously reported for patient H671
that mutations in CTL epitopes were linked to alterations in
CTL responses and the increase in viral load. In this study,
we extended these analyses to further investigate the relation
between CTL escape and the subsequent increase in viral load
and HIV-specific CD4 T-helper responses. In patient H434,
full genome sequencing of HIV-1 biological clones isolated at
12 mo. psc. (clones 8-A3 + 8-F4) and 127 mo. psc. (43-A1,
C1 and E12) was performed. Sixty-one CTL epitopes were
analyzed of which 16 epitopes showed fixation of mutations
between 12 and 127 mo. psc. (Table 1). Seven epitopes were
selected for functional T-cell analysis (Table 1), based on
observed fixation of mutation at residues critical for MHC-
l
Table 1
CTL epitopes with fixed mutations during disease progression in patient H434
a Position of the epitope relative to protein start in HXB2 and epitope name as listed in the HIV-1 Molecular Immunology Database.
b Autologous sequence of the CD8+ T-cell epitopes determined in patient H434 at 12 mo. psc. (upper sequence) and 127 mo. psc. (lower sequence). Sequences are
based on 2 respectively 3 biological clones.
c Most optimally defined CTL epitopes in the Molecular Immunology Database.
d Mutations that disrupt primary or secondary HLA anchor residues. These 7 epitopes were selected for analysis by IFNg Elispot.
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have been previously described to be the most optimally
defined HIV-1 CTL epitopes (HIV-1 Immunology Compen-
dium, http://www.hiv.lanl.gov/content/immunology/pdf/2003/
immuno2003.pdf).Fig. 2. Elispot analysis in individual 434 using 7 wild-type epitopes with various
epitopes could affect T-cell function, IFNg Elispot analysis was performed using sev
months post-seroconversion (C). Responses are shown as the number of spots/1 * 10
(indicated by a dotted line).Functional CD8+ T cells against wild-type and mutant epitopes
in H434
To investigate whether the observed fixed mutations in well-
known and optimally defined CD8+ T-cell epitopes influencedHLA restrictions and their mutants. To determine whether mutations in CTL
en epitopes and their mutated variant at 11 months (A), 75 months (B) and 123
6 CD8+ T cells. Responses higher than 2 times medium are considered positive
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with 7 wild-type epitopes and their observed variants (Table 1)
at several time points in the course of HIV-1 infection. Twelve
months after seroconversion, responses were identified against
3 wild-type (wt) peptides (KK10, SL9, FI9) and their
respective mutants (mKK10, mSL9 and mFI9) (Figs. 2A and
3A). At 75 months after seroconversion, responses against
KK10 and mKK10 had decreased over time but were still
detectable. The SL9-specific CD8+ T-cell responses slightly
increased over time, while mSL9 responses did not change.
Responses against the epitopes FI9 and mFI9 became
undetectable. Interestingly, at 123 mo. psc., no KK10 or
mKK10-specific production of IFNg was observed, and SL9-
specific IFNg+ CD8+ T cells decreased to undetectable levels.
Responses against mSL9 decreased but were still detectable. To
further investigate the occurrence of escape mutations in the
KK10 and SL9 epitope, we analyzed serum-derived viral
sequences for both epitopes at three time points during disease
progression (Table 2). At 12 mo. psc, a heterogeneous
population of 5 different genotypes was detected for the p24
epitope KK10, including the M268L mutation. This mutation
has been shown to be a precursor compensational mutation for
the later R264K mutation (Kelleher et al., 2001). At 78 mo.
psc., the R264K mutation became fixed. The appearance of
mutations coincided with the loss of T-cell reactivity in the
IFNg Elispot to both the WT and MT peptide (Fig. 2 and Table
2), indicative of loss of CD8+ T-cell reactivity due to mutation
of the KK10 epitope. For the HLA-A2-restricted p17 epitope
SL9, fixation of the mutation on the secondary anchor (V82I)
was identified between 78 and 127 mo. psc, which paralleled
the loss of T-cell reactivity to the WT peptide in the IFNg
Elispot (Fig. 2 and Table 2).
Numbers of CD8+ T cells specific for wild-type and mutant
CD8+ T cell KK10 and SL9 epitopes in patient H434
To determine numbers of HLA-B27 and-A2 restricted CD8+
T cells specific for KK10 and SL9, PBMCs from three time
points in the course of HIV infection were analyzed using HLA-
B27 tetramers loaded with peptide KK10 and its mutant, as well
as HLA-A2 tetramers loaded with peptide SL9 and its mutantTable 2
Evolution of epitopes KK10 and SL9 in patient H434
a Months post-seroconversion.peptide (Fig. 3C). HLA-B27-restricted KK10-specific CD8+ T
cells decreased during HIV infection from 1.97% at 11months to
undetectable levels at 123 months after seroconversion. Fur-
thermore, HLA-B27 mKK10 specific CD8+ T cells decreased
from 2.1% at 11 months to 0.35% at 123 months following
seroconversion. HLA-A2-restricted SL9-specific CD8+ T cells
initially increased from 0.46% at 11 months after seroconversion
to 1.0% at 75 months after seroconversion but eventually
decreased again to 0.32% at 123 months after seroconversion.
Staining with the mSL9 tetramer did not result in a tetramer-
positive population. Thus, both numbers as measured by
tetramers and function as identified by IFNg production of
HLA-B27-restricted CD8+ T cells decreased during HIV
infection. Numbers and function of HLA-A2-restricted SL9
specific CD8+ T cells showed only a transient increase.
HIV-specific CD8+ T cells specific for two Gag-p17 epitopes in
patient H671
The observed escape from CD8+ T-cell responses in patient
H434 was compared to a second HIV-1-infected individual
who was documented to harbor viruses that had escaped CD8+
T-cell recognition. We previously documented near-complete
fixation of a mutation in the C-terminal residue of the HLA-
A3-restricted epitope in p17 (RK9: RLRPGGKKK Y R),
which coincided with a decrease in T-cell responses as
measured by IFNg (Fig. 3B). However, at the last time point
analyzed (65 mo. psc), we detected an increase in CD8+ T-cell
responses for both the wild-type and mutant peptide and
hypothesized that this observation could be due to possible
cross-reactivity of CD8+ T cells recognizing a non-mutating
epitope 2 amino acids upstream: KIRLPGGK (KK9; HLA-A3)
(Geels et al., 2003). Here, we extend the previous findings by
using tetramers loaded with the epitopes of interest to
determine numbers of HIV-specific CD8+ T cells specific for
the two epitopes in Gag-p17.
The RK9-specific CD8+ T cells initially decreased from 1.0
to 0.8% during the first 25 months at follow-up and then
strongly increased to 1.6% at 54 mo. psc. This corresponded
with the previously described increase in numbers of IFNg-
producing cells. Finally, the number of RK9 positive CD8+ T
Fig. 3. Analysis of numbers and function of HIV-specific CD8+ T cells in individuals who escape CTL surveillance. In patient H434, CD8+ T-cell responses against
the HLA-B27-restricted KK10 and the HLA-A2-restricted SL9 epitope were measured by IFNg Elispot analysis (A). Tetramer analysis of the number of CD8+ T
cells specific for the KK10, mtKK10, SL9 and mtSL9 epitope in patient H434 (C). Analysis of RK9- and RR9-specific CD8+ T-cell responses by IFNg Elispot in
patient H671 (B). Tetramer analysis of CD8+ T cells was performed in patient H671 using tetramers loaded with either RK9 or the non-mutating epitope 2 amino
acids upstream KK9 (D).
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detected in H671 throughout disease progression. These
observations exclude the previously hypothesized cross-reac-
tivity and indicate that the IFNg is produced by the RK9-
specific CD8+ T-cell population.
Analysis of mutations in HIV-specific CD4+ T-helper epitopes
To determine whether CD4+ T-helper epitopes were
affected by mutations, we analyzed whether predicted HIV-
specific CD4+ T-helper cell epitopes were altered through
sequence variation. We found that in patient H434 the
mutation in the KK10 epitope overlapped with a T-helperTable 3
Mutations in commonly recognized CD4+ T-cell epitopes
Patient Regiona Common
H434 p24 (119–133) TNNPPIP
p24 (23–40) WKVV/I
p24 (31–48) AFS/NPE
p24 (81–102) DRVHPV
p24 (141–158) IVRMYS
p24 (164–181) YVDRFY
p17 (77–94) SLYNTV
Nef (184–199) KFDSR/H
Int (250–267) VIQDNS
H671 p17 (17–34) EKIRLRP
Nef (11–128) LWVYHT
a Amino acid position of the epitope relative to protein start in HXB2 and epitop
b Autologous sequences of CD4+ T helper epitopes in patients H434 and H671. I
(H434: 12 and 127 mo. psc; H671: 2 and 47 mo. psc).epitope TNNPPIPBGEIYKRW (DQ13), whereas no HLA-
class-II-restricted CD4+ T-helper epitopes were found to be
affected by fixation of mutation in patient H671 (data not
shown). Next, we included peptides which are known to be
broadly recognized by CD4+ T-helper cells in clade-B-
infected patients with different genetic backgrounds (Rosen-
berg et al., 1997; Younes et al., 2003; Kaufmann et al., 2004)
(Table 3) In patient H434, the fixation of nine residues (Gag,
Nef and RT) and in patient H671 fixation of two mutated
residues (Gag, Nef) was observed between early and late time
points in the course of HIV-1 infection. The two mutations in
patient H671 overlapped with mutations in HIV-specific CTL
epitopes.ly recognized peptideb Reference
BGEIYKR/KW Kaufmann et al., 2004
EEKAFS/NPEVIPMF Kaufmann et al., 2004
VIPMFS/TALSEGAT Rosenberg et al., 1997
HAGPIA/PVPGQMREPRGS Kaufmann et al., 2004
PT/VSILDIRQGPK Kaufmann et al., 2004
KTLRAEQAS/TQEV Kaufmann et al., 2004
/IATLYCVHQRIEV Kaufmann et al., 2004
LAFH/RHMARELH Younes et al., 2003
DIKV/AVPRRKAKI Kaufmann et al., 2004
GGKKK/RYKLHKI Kaufmann et al., 2004
GQGYFPDWQ/DNYT Kaufmann et al., 2004
e name as listed in the HIV-1 Molecular Immunology Database.
n bold are amino acid residues which became fixed during disease progression
M.J. Geels et al. / Virology 345 (2006) 209–219214CTL escape, viremia and CD4+ T-helper responses
Gag-specific CD4+ T cells producing IFNg, IL-2 or IL-2 and
IFNgwere analyzed (Jansen et al., 2005) at the same time points
as used for the CD8+ T-cell measurements in both patients to
investigate whether the observed loss of CD8+ T-cell responses
was accompanied by loss of CD4+ T-helper responses in
relation to the observed increase in viral load. Absolute numbers
of HIV-specific cytokine-producing CD4+ T cells are shown
since this is a more reliable read-out than percentages, as we
have previously described (Jansen et al., 2005). For patient
H434, Gag-specific IL-2+ CD4+ T cells decreased from 1870
cells/ml 11 mo. psc. to 148 cells/ml 75 mo. psc. and became
undetectable 127 mo. psc. (Fig. 3A). Similar results were
observed for IL-2+ and IFNg+ cells (1360 cells/ml 11 mo. psc.,
111 cells/ml 75 mo. psc. and undetectable levels at 123 mo. psc.
Fig. 3C). As shown in Fig. 3A, Gag-specific IFNg+ CD4+ T
cells decreased from 1955 cells/ml to 74 cells/ml but increased
during the last 48 months of follow-up to 240 cells/ml. In
patient H671, levels of HIV-specific IFNg+ and IL-2+ CD4+ T
cells fluctuated during the first 80 months of follow-up and
eventually decreased to 429 and 165 cells/ml respectively (Figs.
3D, E). As shown in Fig. 3F, numbers of IL-2+ and IFNg+ CD4+
T cells initially decreased from 417 to 96 cells/Al at 85 months
after seroconversion and then increased again to 400 cells/ml at
95 months following seroconversion.
Taken together, loss of HIV-specific CD8+ T-cell responses
(both wild-type and mutant) is not per se accompanied by a
decrease in HIV-specific T-helper responses. Interestingly, the
slope of viral RNA load increase determined by linear
regression in patient H434 (3690 cp/ml T 762) was approxi-
mately 10-fold higher than in patient H671 (377.5 cp/ml T
42.7), suggesting that high viremia may be responsible for the
observed decrease in HIV-specific IL-2+ and IL-2 and IFNg+
CD4+ T cells (Fig. 4).
Discussion
Analysis of the mechanisms associated with failure of T-cell
function during HIV-1 infection is of importance when a
vaccine is to be realized with the aim of eliciting effective,
protective and sustainable T-cell responses. In this report, we
describe two HIV-1-infected individuals who escape recogni-
tion of functional HIV-specific CD8+ T cells during disease
progression and relate these responses to CD4+ T-cell function.
From full genome sequence analysis of HIV-1 biological clones
generated from patient H434, we identified at least 7 known
epitopes acquiring mutations on critical residues during disease
progression. However, upon CD8 recognition analysis, we
identified that CD8+ T-cell responses against only two epitopes
(KK10 and SL9) were readily detected, and mutations of critical
residues led to an abrogation of existing T-cell responses.
Previous reports have demonstrated that the HLA-B27-
restricted epitope KK10 is associated with effective control of
viremia (Goulder et al., 1997; Kelleher et al., 2001) and that a
distinct sequence of mutations (L268M, R268K) in this epitope
leads to loss of CTL recognition correlating with diseaseprogression and preceding viremia breakthrough (Kelleher et
al., 2001; Feeney et al., 2004). Interestingly, in patient H434, we
observed the same order in appearance of mutations, again
supporting the concept of structural constraint on epitope evo-
lution. The mutant KK10 epitope has previously been shown to
be less adequately presented by HLA-B27 compared to the wild-
type KK10 due to inadequate processing. Furthermore, recog-
nition of the variant peptide was shown to be reduced, but not
fully abrogated, possibly due to rapid dissociation for the B27-
molecule (Goulder et al., 1997). Despite this, in our assays using
a high concentration of peptide, the mutant KK10 was able to
stimulate T cells resulting in IFNg production. Furthermore,
although the peptide will more rapidly dissociate from the B27
molecule, the overall orientation of the peptide in the binding
groove was shown not to be altered by the R to K mutation
(Goulder et al., 1997). Therefore, we were able to synthesize
HLA-B27 tetramers containing the mutant peptide. Even more,
we were able to specifically stain T cells recognizing the mutant
KK10 in the context of HLA-B27 to the same extent as T cells
recognizing the wt KK10.
It is possible that the effects of acute T-cell responses have
been missed due to the late start of our analysis at 12 mo. psc. At
this time point, minimal T-cell reactivity was detected against
the FL9 wild-type and mutant peptides, and this may well
represent remnants of T-cell responses elicited earlier during
infection. T-cell responses to Vpr and Vif are known to
contribute significantly to the total CD8+ T-cell responses in
HIV-infected individuals (Altfeld et al., 2001), and the observed
mutation in Vpr-AL9 (Table 1) has previously been shown to
confer fitness loss upon the virus (Altfeld et al., 2001). The
appearance of the well-documented HLA-A2-restricted SL9 T-
cell response fits the previous finding as CTL directed against
this epitope only appear during chronic infection (Goulder et al.,
2001). We previously hypothesized that the increase in CD8+ T-
cell responses against the HLA-A3-restricted epitope RK9 and
its mutant RR9 could be due to possible cross-reactivity of
CD8+ T cells recognizing a non-mutating HLA-A3-restricted
epitope 2 amino acids upstream: KK9 (Geels et al., 2003).
Analyzing the number of RK9-specific CD8+ T cells as well as
the number of KK9-specific CD8+ T cells demonstrated that
continued T-cell reactivity despite the occurrence of escape
mutations is not likely to be a consequence of cross-reactivity.
In patient H434, the occurrence of escape mutation was
paralleled by loss of CTL control, a subsequent increase in viral
load and the eventual depletion of HIV-specific CD4+ T cells
producing IL-2 or IL-2 and IFNg. Interestingly, this profile was
not observed in patient H671, in whom escape was associated
with an on average ten-fold less increase in viral load. These
differences in viral load and its effect on CD4+ T-helper cell
function fit the model proposed by Younes et al. (2003), which
indicates that the presence of IL-2-producing CD4+ T cells with
self-renewal capacity is restricted to aviremic individuals. In
individuals with a high viral load, HIV-specific CD4+ T cells are
preferentially induced to further differentiate into a population
of IFNg-only-producing CD4+ T cells, which lack proliferative
potential upon re-stimulation by antigen. Thus, the observed
loss of HIV-specific IL-2+ and IL-2+ and IFNg+ CD4+ T cells
Fig. 4. HIV-specific T-helper responses in two individuals who escape CTL surveillance. Representative FACsplots demonstrating the production of IFNg and IL-2
of CD3+ CD4+ T cells in the absence of stimulus (medium), after stimulation with a Gag-peptide pool (Gag) and a polyclonal stimulus (PMA/Ionomycin) in patient
H671 at 0.2 months post-seroconversion. Percentages of CD3+ CD4+ T cells (left panel) and cytokine-producing CD3+ CD4+ T cells (right panel) are indicated.
Longitudinal analyses of the absolute number of IFNg+ (B), IL-2+ (C) and IL-2, and IFNg+ CD4+ T cells (D) are shown for patient H434 and patient H671 (E–G).
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two patients. Furthermore, these data suggest that CTL escape is
not necessarily linked to HIV-specific CD4+ T-cell responses
but imply that CD4+ T-helper responses are influenced by the
level of viremia, as has been reported before (McNeil et al.,
2001; Iyasere et al., 2003; Palmer et al., 2004). However,
studies in larger cohorts are warranted to further elucidate the
role of CD4+ T-cell responses in relation to viral load in subjects
who escape CTL recognition.Concurrent with the viral sequence evolution affecting CTL
epitopes, mutations may arise in CD4+ T-cell epitopes that
influence loss of T-cell function during HIV-1 infection.
Indeed, CD4+ T-cell epitope escape has been described in the
mice persistently infected with lymphocytic choriomeningitis
virus (LCMV) (Ciurea et al., 2001). Although promiscuity has
previously been reported for CD4 epitopes and their restricting
haplotypes (Kaufmann et al., 2004), we found mutations in
class-II-restricted peptides (p17, p24 and Nef), which are
M.J. Geels et al. / Virology 345 (2006) 209–219216known to be broadly recognized in clade-B-infected patients
with different genetic backgrounds. Of note, mutations in CD4+
T-cell epitopes overlapped with mutations in CD8+ T-cell
epitopes and are very likely primarily induced by class-I-
restricted CTL responses. Mutations at these residues may prove
to be a more effective means of viral escape since not only CTL
responses, but also a more diverse array of responses are lost.
Taken together, we presented here two patients escaping HIV-
1 CTL recognition. Although both escape CTL recognition, an
apparent difference in control of viremia is observed between the
two patients, which coincides with differences in HIV-1-specific
CD4+ T-cell responses. This suggests that loss of T-cell
recognition after CTL escape is not directly linked to HIV-
specific CD4+ T-cell responses but that the increased viremia
after CTL escape may influence CD4+ T-helper responses as
suggested previously (Jansen et al., 2005).
Materials and methods
Patient characteristics
Two patients (H434 and H671) were selected from the
Amsterdam Cohort Studies (ACS) on HIV-1 infection and
AIDS based on low viral loads and high CD4+ T-cell numbers
at study entry and a stable viral load during the first years of
follow-up. After some years of follow-up, a sudden increase in
viral load was observed which was paralleled by decreasing
CD4+ T-cell numbers. Patient H671 demonstrated a switch in
virus phenotype to an SI variant at month 62, a time point after
the rise in viral loads had occurred (data not shown), while
patient H434 demonstrated NSI variants throughout. Both
patients were heterozygous for the CCR5D32 allele and wild-
type for CCR2 and SDF-1 alleles.
Patient H434 who entered the ACS remained therapy naive
for 132 months. By linear regression analysis, we determined
that the RNA viral load increased with a slope of 3690 copies/
ml/month (standard deviation (SD) 762) The slope of CD4+ T-
cell decline was found to be 3.7 cells/ml/month (SD 0.5). The
patient’s HLA type was A2, 28, B7, 27, Cw02, DR09, 13,
DQ03 and 06. Characteristics of the second patient (H671)
have been previously described (Geels et al., 2003). The HLA
type of this patient is HLA A3, 36, B15, 51, Cw3, 6 DR4, 8,
DQ7 and for this individual sequential fixation of mutations in
documented CTL epitopes or reactive peptides has been
reported to coincide with alteration of T-cell responses and
increasing viral loads during a 5-year follow up period (Geels
et al., 2003). The average increase in viral load was 377.5
copies/ml/month (SD 42.7), whereas CD4+ T-cell decline was
9.8 cells/ml/month (SD 1.1). Informed written consent was
obtained from both patients, and this study was approved by
the Medical Ethical Committee of the Academic Medical
Center.
Biological cloning, full-length and serum HIV-1 sequencing
Viral DNA was extracted (Fblood and body fluid DNA_
isolation kit, QIAGEN, Valencia, CA, USA) from one millionPBMCs infected with biological clones generated through
limiting dilution (Koot et al., 1996). Sequencing of viral DNA
was performed as previously published (Harris et al., 2002) with
minor modifications.
To investigate the occurrence of escape mutations in the
HLA-B27-restricted KK10 and the HLA-A2-restricted SL9
epitope, we analyzed serum-derived viral sequences for both
epitopes at three time points during disease progression.
Serum-derived viral nucleic acids were isolated using a silica-
based method (Boom et al., 1991). Reverse transcription and
polymerase chain reactions (PCRs) were performed using
previously published methods with slight modifications
(Cornelissen et al., 1997). SL9 sequences were reversed
transcribed using primers Gag-5 (5V CCC CCACTGTATT-
TAACATGGTG 3V) and KK10 with TFSM (5V TTATG-
GAATTCATGAAGCTCTCTTCTGGTGG 3V). First PCR
reaction for SL9 was performed using Louw1gag (5V TTG
ACT AGC GGA GGC TAG AA 3V) + Gag 5 and TFSM and
SK145 (5V AGT GGG GGG ACATCA AGC AGC CAT GCA
AAT 3V) for KK10. Secondary p17 PCRs were done with gag-
2 (5V CAT AAG CTT GGG AAA AAA TTC GGT TAA GGC
C 3V) + gag-3 (5V TCG GCT CCC TCC ATG TCT CC 3V) and
for p24 epitope with p24/p7 (5V GGG GAA GTG ACA TAG
CAG GAA CTA 3V) and bgcom (5V TCC CTA AAA AAT
TAG CCT 3V).
All positive PCR products (full genome + serum) were bi-
directionally sequenced with the BigDye Terminator Cycle
Sequencing kit (ABI, Foster City CA, USA) and analyzed
using an ABI 377 automated sequencer (ABI). Alignment of
the sequences was straightforward and was performed manu-
ally using BioEdit 7.0 (T. Hall, Ibis Therapeutics, CA) and
Textpad (Helios Software Solutions).
IFNc Elispot assay
IFNg-producing antigen-specific CD8+ T cells were enu-
merated by IFNg-specific Elispot assays as previously de-
scribed (Lalvani et al., 1997; van Baarle et al., 2001) using 96-
well nylon-backed plates (Nunc, Roskilde, Denmark) and
IFNg-specific monoclonal antibodies (MABTECH, Stock-
holm, Sweden). PBMCs were added at 105 cells per well in
triplicate in the absence or presence of 10 Ag/ml peptide and
incubated overnight at 37 -C. PHA stimulation served as a
positive control to test the capacity of PBMCs to produce
IFNg. IFNg-producing cells were detected as dark spots and
counted using an automated spot reader (AELVIS, Software
version 3.2, Hanover, Germany). HIV-1-specific IFNg
responses were reported as number of spot-forming units
(SFU) per 106 CD8+ T cells. Only samples with at least twice
the number of spots observed with media alone were
considered positive.
Peptides that were used representing wild-type and
mutant epitopes used in this study are described in Table
1 and were synthesized by the Dutch Cancer Institute,
Amsterdam, The Netherlands. Peptides were dissolved in
dimethyl sulfoxide (DMSO) at 100 mg/ml and stored at
20 -C.
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MHC class I tetramers complexed with virus-specific
peptides were produced as previously described (Altman et
al., 1996; Kostense et al., 2002). Monomers were analyzed
biochemically for proper folding. Tetramers were tested for T-
cell recognition in HLA-matched HIV-positive individuals
showing T-cell reactivity against the specific peptide (staining
between 0.1 and 0.4%, data not shown). PBMCs were thawed,
and 1.5  106 cells were stained in PBS supplemented with
0.5% (v/v) bovine serum albumin (PBA) with MHC class I
tetramers and fluorochrome-conjugated monoclonal antibodies.
Next, cells were fixed in Cellfix (Beckton Dickinson, San Jose´,
California, United States), and at least 250,000 events were
acquired using a FACSCalibur flow cytometer (BD). Lympho-
cytes were gated by forward and sideward scatter. Data were
analyzed using the software program CELL Quest (BD).
Detection of HIV-specific CD4+ T cells
Gag-specific CD4+ T cells were quantified as previously
described (Jansen et al., 2005). In short, cryopreserved
PBMCs were thawed using RPMI-1640 medium supplemen-
ted with penicillin, streptomycin and 20% inactivated FCS and
subsequently washed in 10% FCS medium. Cells were
aliquoted at 2  106 cells per ml in round-bottom tubes
(polystyrene, Falcon, BD). Cells were stimulated with a Gag-
specific peptide pool (15 mers with 11 overlap, HXB2, NIH
AIDS Research and Reagent program, Bethesda, Maryland,
United States) in the presence of co-stimulation (2 Ag/ml
aCD28 (Sanquin Reagents) and 2 Ag/ml aCD49d (Pharmingen,
San Jose´, California, United States). The concentration of the
individual peptides within the pool was 2 Ag/ml. As a positive
control, PMA/Ionomycin was used. After 1 h, Brefeldin A (BD)
was added, and cells were incubated for another 5 h at 37 -C,
5% CO2. Next, cells were fixed and permeabilized (permeabi-
lization kit, BD) and stained with aCD3-PerCP, aCD4-APC,
aIL-2-PE and aIFNg-FITC (BD) for 20 min at 4 -C. At least
300,000 events were acquired by flow cytometry as described
before. Frequencies of IFNg and IL-2-producing cells were
reported after subtraction of the frequencies in medium controls.
Cytokine production was above the background levels observed
in HIV-negative individuals (median 0.02%, range 0–0.03, data
not shown).
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